

Preliminary Programme

Paris, France
5-7 November 2025

Wednesday, 5 November 2025

14:30-19:00 Lymphoma Working Party Scientific Business Meeting

Thursday, 6 November 2025

09:00-09:10 Welcome from the organizers

Ali Bazarbachi (LB)

**09:10-11:00 Session I: Aggressive lymphomas – DLBCL
Chair: Bertram Glass (DE)**

09:10-09:40 New classifiers: does it matter for treatment

Fabrice Jardin (FR)

09:40-09:50 Discussion

Case-based discussion third line and beyond (CART vs bispecifics):

09:50-10:00 Junior, detailed case presentation

10:00-10:30 Critical discussion of the presented case and state-of-the-art

10:30-11:00 Is there still a role for autologous SCT in DLBCL Yes/No

10:30-10:40 Yes

Christian Gisselbrecht (FR)

10:40-10:50 No

Bertram Glass (DE)

10:50-11:00 Discussion

11:00-11:30 Coffee break

**11:30-12:50 Session II: Mantle cell lymphoma
Chairs: Morgane Cheminant (FR) & Peter Dreger (DE)**

11:30-11:50 New classifiers: does it matter for treatment

Morgane Cheminant (FR)

11:50-12:00 Junior presents a typical case of mantle cell lymphoma with several lines of treatment

Clemence Loiseau (FR)

12:00-12:20 Discussion of the non-cellular therapy strategies

Marco Ladetto (IT)

12:20-12:40 Discussion of the cellular therapy options: transplant, CART-T and bi-specifics

Peter Dreger (DE)

12:40-12:50 Discussion

13:00-14:00 Lunch break

**14:00-15:20 Session III: Indolent B cell lymphoma
Chair: Nour Moukalled (LB)**

14:00-14:20 New classifiers in follicular lymphoma: does it matter for treatment

Sandrine Roulland (FR)

14:20-14:30 Junior presents a typical case of follicular lymphoma with several lines of treatment

14:30-14:50 Discussion of the non-cellular therapy strategies including bispecifics

Silvia Montoto (UK)

14:50-15:10 Discussion of the cellular therapy options: transplant, CART-T

15:10-15:20 Discussion

**15:30-16:50 Session IV: Peripheral T cell lymphoma
Chair: Gandhi Damaj (FR) & Olivier Tournilhac (FR)**

15:30-15:50 New classifiers in TFH: does it matter for treatment

François Lemonnier (FR)

15:50-16:00 Case presentations selected among the submitted cases

16:00-16:20 Standard treatment of the T-cell lymphoma with emphasis on allogeneic and autologous Transplantation + Q&A

Norbert Schmitz (DE)

16:20-16:40 The pipeline of T cell engaging therapy for T cell lymphoma: where do we stand? + Q&A

Pier Luigi Zinzani (IT)

16:40-16:50 Discussion

Preliminary Programme

Paris, France
5-7 November 2025

Thursday, 6 November 2025 – continued

17:00-17:30 Coffee break

17:30-18:20 **Session V: Cutaneous T cell lymphoma** **Chair: Alberto Mussetti (ES) & Eva Domingo (ES)**

17:30-17:40 Case presentations selected among the submitted cases
17:40-18:10 CTCL: State-of-the-art treatment and role of cellular therapy
18:10-18:20 Discussion

Eva Domingo (ES)

Friday, 7 November 2025

09:00-11:00 **Session VI: Hodgkin lymphoma first line** **Chair: Anna Sureda (ES) & Alina Tanase (RO)**

09:00-09:20 New classifiers in classical HL: does it matter for treatment
09:20-09:30 Junior presents one case of NLPHL with multiple lines of therapy
09:30-09:50 State-of-the-art treatment of NLPHL and role of cellular therapy
09:50-10:00 Junior presents one case of classical HL, advanced stage
10:00-10:30 Choices and options in the first line
10:30-10:40 Discussion

Cédric Rossi (FR)

Dennis Eichenauer (DE)

Anna Sureda (ES)

10:40-11:10 Coffee break

11:10-12:30 **Session VII: Hodgkin lymphoma in relapse and difficult to treat cases** **Chair: Ali Bazarbachi (LB) & Luca Castagna (IT)**

11:10-11:20 Junior presents case of relapsed/refractory Hodgkin lymphoma
11:20-11:50 Strategies at relapse
11:50-12:00 A case of Hodgkin lymphoma with long-term complications
12:00-12:15 Lung Cancer Screening in Hodgkin Lymphoma
12:15-12:30 Survivors - a UK national initiative
Discussion

Ali Bazarbachi (LB)

Kim Linton (UK)

12:30-13:30 Lunch break

13:30-14:45 **Session VIII: Supportive care in cellular therapy** **Chairs: Anna Ossami Saidy (DE) & Rémy Duléry (US)**

13:30-13:50 Management of cytopenia after CART
13:50-14:10 Neurological complications
14:10-14:30 From CRS to HLH following CART
14:30-14:45 Discussion

Martina Pennisi (IT)
Roser Velasco (ES)
Matteo Doglio (IT)

14:45-16:00 **Session IX: Innovation in allotransplant** **Chair: Yasmina Serroukh (NL)**

14:45-15:05 Invariant NKT cells and risk of GVHD
15:05-15:30 Artificial intelligence and multi-omics in allotransplant
15:30-15:50 Methodology and bias in registry studies
15:50-16:00 Discussion

Jacques-E. Galimard (FR)

16:00-16:10 **Closing remarks**